A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №2, 2026

more

A.I. Burnasyan  FMBC clinical bulletin. 2026 № 2

Y.D. Udalov1, M.I. Tokareva2, Y.S. Kitaeva3, E.Yu. Sumorokova2, E.V. Kuznetsova2

Features Of Immunological Status in Patients with Hodgkin’s Lymphoma
Associated with Pathogenetic Therapy

1International Office, State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russiа

2Federal State Budgetary Institution of Higher Professional Education «Urals State Medical University»,  Moscow, Russia 

3Russian National Research Medical University named after. N. I. Pirogova,  Moscow, Russia

Contact person: Kitaeva Julya Sergeevna: jkhema@yandex.ru

 

Abstract
Background: hodgkin’s lymphoma (HD) is characterized by pronounced violations of the mechanisms of immune surveillance caused by overexpression of PD-L1/L2 molecules by tumor cells. Despite the high effectiveness of standard polychemotherapy (PCT), some patients have a refractory or recurrent course of the disease. The introduction of checkpoint inhibitors such as nivolumab makes it possible to overcome this barrier, however, the effect of these drugs on the long-term immune status of patients remains poorly understood, which determines the relevance of this study.
Objective: to conduct a comparative analysis of immune status indicators in patients with Hodgkin’s lymphoma, depending on the type of pathogenetic therapy.
Materials and methods: the study included 10 patients with HD receiving PCT and 9 patients receiving nivolumab in a mono-mode. The control group consisted of 9 healthy volunteers. The immune status was assessed by flow cytometry with immunogram analysis. Statistical data processing was performed using the Kraskell–Wallis and Mann-Whitney criteria.
Results: standard PCT leads to the formation of a hyporeactive immune profile, accompanied by a decrease in the level of CD3+ T lymphocytes and CD4+ T helper cells compared with the control group. The use of nivolumab helps restore the functional activity of the T-cell link, which is accompanied by higher rates of CD3+, CD4+ and T-NK cells compared with the PCT group.
Conclusions: the use of nivolumab in patients with PC is not only a targeted effect on the tumor clone, but also a tool for modulating immunity

Keywords: Hodgkin’s lymphoma, nivolumab, polychemotherapy, immune status, PD-1 inhibitors, secondary immunodeficiency, oncohematology

For citation: Udalov YD, Tokareva MI, Kitaeva YS, Sumorokova EYu, Kuznetsova EV. Features Of Immunological Status in Patients with Hodgkin’s Lymphoma Associated with Pathogenetic Therapy. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2026.2:88-92. (In Russian) DOI: 10.33266/2782-6430-2026-2-88-92

 

REFERENCES

  1. Demina, E. A. «General Principles of Lymphoma Diagnosis.» Russian Clinical Guidelines for the Diagnosis and Treatment of Malignant Lymphoproliferative Diseases 2018 (2018): 9. (In Russ.)
  2. Lepik K.V., Mikhailova N.B., Kondakova E.V., Tsvetkova L.A., Zalyalov Yu.R., Borzenkova E.S., et al. Efficacy and safety of nivolumab in the treatment of recurrent and refractory classical Hodgkin’s lymphoma: experience of Pavlov First Saint Petersburg State Medical University. Onkogematologiya, 13 (4), 17-26. (In Russ.)
  3. Forster, Martin David, and Michael-John Devlin. «Immune checkpoint inhibition in head and neck cancer.» Frontiers in oncology 8 (2018): 310.
  4. Lyadov VK, Nersesova TA, Pokataev IA, Lyadova MA. Predictors for the development of immune-mediated adverse events during treatment with immune checkpoint inhibitors. P.A. Herzen Journal of Oncology. 2021;10(2):55 61. (In Russ.) https://doi.org/10.17116/onkolog20211002155
  5. Gusak, Artem Aleksandrovich, et al. «Classic Hodgkin’s Lymphoma: Tumor Structure and Prognostic Significance of the Immune Microenvironment.» Clinical Oncohematology. Fundamental Research and Clinical Practice» 16.3 (2023): 242-262.
  6. Patrakeeva, Veronika Pavlovna. «Cytokine Regulation of the Proliferative Activity of Peripheral Blood Cells.» Human Ecology 12 (2015): 28-33. . (In Russ.)
  7. Tsaplina, Natalia Sergeevna, et al. «Modern Approaches to the Treatment of Recurrences and Refractory Forms of Hodgkin’s Lymphoma: A Review of the Literature and Own Data.» Modern Oncology 24.3 (2022): 319-324. (In Russ.)
  8. Demina, Elena Andreevna, et al. «Hodgkin’s Lymphoma.» Modern Oncology 22.2 (2020): 6-33. (In Russ.)
  9. Pei, Fajun, et al. «Efficacies and toxicities of seven chemotherapy regimens for advanced Hodgkin lymphoma.» Frontiers in Pharmacology 12 (2021): 694545.
  10. Gunturi, Anasuya, and David F. McDermott. «Nivolumab for the treatment of cancer.» Expert opinion on investigational drugs 24.2 (2015): 253-260.
  11. Ilyin, N. V., and Yu. N. Vinogradova. «Late Complications of Hodgkin’s Lymphoma Therapy.» Practical Oncology 8.2 (2007): 96-101. . (In Russ.)

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 13.04.2026. Accepted for publication: 15.05.2026

© 2026 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top